RAPT - RAPT Therapeutics Inc
RAPT Therapeutics Inc Logo

RAPT - RAPT Therapeutics Inc

https://www.rapt.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company is headquartered in South San Francisco, California.

52W High
$26.56
52W Low
$5.66
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
-0.10
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-10.73
EV/Revenue (<3 favorable)
677.37
P/S (TTM) (<3 favorable)
411.22
P/B (<3 favorable)
1.30
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
0.42%
Institutions (25–75% balanced)
102.56%
Shares Outstanding
16,537,800
Float
3,912,500
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
1,527,000
EPS (TTM)
-14.80
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.78%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-1.00
Momentum
Bearish momentum
Value
1.4161
Previous
1.1819
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025